NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 35 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,587 | -100.0% | 1,000 | -100.0% | 0.00% | -100.0% |
| Q4 2020 | $64,681,000 | -0.6% | 46,390,000 | 0.0% | 0.06% | -15.8% |
| Q3 2020 | $65,053,000 | -38.2% | 46,390,000 | -23.2% | 0.08% | -37.7% |
| Q2 2020 | $105,347,000 | +23.9% | 60,425,000 | -5.5% | 0.12% | +7.0% |
| Q1 2020 | $85,025,000 | -24.2% | 63,975,000 | -11.4% | 0.11% | +10.7% |
| Q4 2019 | $112,242,000 | +22.7% | 72,175,000 | +8.4% | 0.10% | +14.4% |
| Q3 2019 | $91,443,000 | +28.3% | 66,555,000 | +23.5% | 0.09% | +36.4% |
| Q2 2019 | $71,274,000 | -12.7% | 53,905,000 | -12.3% | 0.07% | -18.5% |
| Q1 2019 | $81,630,000 | +5.0% | 61,500,000 | -5.6% | 0.08% | -4.7% |
| Q4 2018 | $77,766,000 | -39.9% | 65,145,000 | -13.5% | 0.08% | -27.4% |
| Q3 2018 | $129,343,000 | +6.0% | 75,285,000 | -10.2% | 0.12% | -1.7% |
| Q2 2018 | $122,059,000 | – | 83,875,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aequim Alternative Investments LP | 24,000,000 | $30,877,000 | 5.11% |
| Alken Asset Management Ltd | 360,000 | $457,000 | 1.90% |
| III Capital Management | 3,500,000 | $4,481,000 | 1.64% |
| SHENKMAN CAPITAL MANAGEMENT INC | 3,920,000 | $5,113,000 | 0.76% |
| CSS LLC/IL | 6,842,000 | $8,745,000 | 0.69% |
| DeepCurrents Investment Group LLC | 10,408,000 | $13,373,000 | 0.65% |
| SSI INVESTMENT MANAGEMENT LLC | 4,334,000 | $5,554,000 | 0.49% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,250,000 | $23,476,000 | 0.34% |
| MACKAY SHIELDS LLC | 24,612,000 | $31,641,000 | 0.29% |
| Nicholas Investment Partners, LP | 1,115,000 | $1,429,000 | 0.28% |